{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-048520","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.706182+00:00","generated_at":"2026-05-21T07:58:59.311181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CytoSorbents Q1 product rev $8.7M (-3%); FDA denies DrugSorb-ATR De Novo","bullets":["Product revenue $8.7M, flat constant currency vs Q1 2024 $9.0M; gross margin 71% vs 77%.","Net loss improved to $1.5M ($0.02/shr) from $6.1M; adjusted net loss $3.7M ($0.06/shr).","FDA denied DrugSorb-ATR De Novo on Apr 25, 2025; company plans formal appeal for 2025 decision.","Rights offering raised $6.8M net; cash & restricted cash $13.1M at Mar 31 vs $9.8M Dec 31.","Germany sales disruption offset by E.U. distributor growth; opened Dubai subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-048520","json":"https://secwatch.observer/filing/0001104659-25-048520.json","markdown":"https://secwatch.observer/filing/0001104659-25-048520.md","text":"https://secwatch.observer/filing/0001104659-25-048520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925048520/0001104659-25-048520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465925048520/tm2515144d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T07:58:59.311181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}